321371-29-3

Usage

Uses

Used in Pharmaceutical Synthesis:
4-Thiazolecarboxylic acid, 2-(chloromethyl)-, methyl ester (9CI) is used as a building block in the synthesis of pharmaceuticals for its potential to contribute to the development of new drugs. The chloromethyl group in the compound allows for versatile chemical modifications, facilitating the creation of complex molecules with potential therapeutic applications.
Used in Agrochemical Development:
In the agrochemical industry, 4-Thiazolecarboxylic acid, 2-(chloromethyl)-, methyl ester (9CI) is utilized as a key intermediate in the synthesis of agrochemicals, contributing to the development of effective and novel compounds for crop protection and other agricultural applications.
Used in Organic Synthesis:
As a versatile chemical, 4-Thiazolecarboxylic acid, 2-(chloromethyl)-, methyl ester (9CI) is employed in organic synthesis for the preparation of complex molecules. Its unique structure and functional groups enable chemists to explore various synthetic pathways, leading to the discovery of new compounds with potential applications in different fields.
Used in Chemical Biology Research:
4-Thiazolecarboxylic acid, 2-(chloromethyl)-, methyl ester (9CI) serves as a research tool in chemical biology, where it can be used to probe biological systems and investigate molecular interactions. Its unique structure and reactivity make it a valuable compound for studying biological processes and developing new insights into molecular mechanisms.

Upstream product

• 321371-28-2 methyl 2-(dichloromethyl)-4,5-dihydro-1,3-thiazole-4-carboxylate 
• 124-41-4 sodium methylate 

Relevant academic research and scientific papers

Incorporation of heterocycles into the backbone of peptoids to generate diverse peptoid-inspired one bead one compound libraries

Combinatorial libraries of peptoids (oligo-N-substituted glycines) have proven to be useful sources of protein ligands. Each unit of the peptoid oligomer is derived from 2-haloacetic acid and a primary amine. To increase the chemical diversity available in peptoid libraries, we demonstrate here that heterocyclic halomethyl carboxylic acids can be employed as backbone building blocks in the synthesis of peptoid-based oligomers. Optimized conditions are reported that allow the creation of large, high quality combinatorial libraries containing these units.

FARNESOID X RECEPTOR AGONISTS

The present invention relates to famesoid X receptors (FXR, NR1H4) FXR is a member of the nuclear receptor class of ligand-activate transcription factors More particularly, the present invention relates to compounds useful as agonists for FXR, pharmaceutical formulations comprising such compounds, and therapeutic use of the same Novel isoxazole compounds are disclosed as part of pharmaceutical compositions for the treatment of a condition mediated by decreased FXR activity, such as obesity, diabetes, cholestatic liver disease, liver fibrosis, and metabolic syndrome

ARYL DICARBOXAMIDES

The present invention is related to aryl dicarboxamides of formula (I) and use thereof for the treatment and/or prevention of obesity and/or metabolic disorders mediated by insulin resistance or hyperglycernia, comprising diabetes type I and/or II, inadequate glucose tolerance, insulin resistance, hyperlipidemia, hypertriglyceridemia, hypercholes-terolemia, polycystic ovary syndrome (PCOS). In particular, the present invention is related to the use of aryl dicarboxamides of formula (I) to modulate, notably to inhibit the activity of PTPs. A is an airninocarbonyl moiety; Cy is an aryl, heteroaryl, aryl-heteroaryl, heteroaryl-aryl, aryl-aryl, cycloalkyl or heterocycle group; n is either 0 or 1; R1 and R2 are independently from each other is selected from the group consisting of hydrogen or C1-C6-alkyl; R4 and R5 are each independently from each other selected from the group consisting of H, hydroxy, C1-C6 alkyl, carboxy, C1-C6 alkoxy, C1-C3 alkyl carboxy, C2-C3 alkenyl carboxy, C2-C3 alkynyl carboxy, amino or R4 and R5 may form an unsaturated or saturated heterocyclic ring, whereby at least one of R4 or R5 is not a hydrogen or C1-C6 alkyl.

An efficient, practical approach to the synthesis of 2,4-disubstituted thiazoles and oxazoles: Application to the synthesis of GW475151

GlaxoWellcome Research and Development, Chemical Development Division, Medicines Research Centre,. A new method for the synthesis of 2,4-disubstituted oxazoles and thiazoles and 2,4,5-trisubstituted oxazoles from readily available starting materials is described. The methodology has been applied on multigram scale and involves transfer of oxidation state through a molecular framework. In particular the oxazole-containing amino acid fragment of the 5,5-transfused lactam GW475151, 1, has been prepared in excellent yield and purity.